This World Menopause Day, we’re proud to share we have supported this pioneering research into menopause and women's immune systems, led by Emma S Chambers at Queen Mary University of London. This is a brilliant example of how funding innovative ideas in health can lead to advances in our understanding – this time around menopause and women’s immune systems. These findings could have a huge impact for women in our East London community and beyond. Read more: bit.ly/492IYeG

On stage at the Women’s Health Summit in Zurich, Dr. Valentina Vinante, gynecologist and scientific advisor for the Women's Brain Foundation, reminded us that menopause is not a disease. It’s a transition, and it starts in the #brain. A profound message on prevention, long-term health, and the importance of science that truly includes women. If you want to know more, listen to Dr. Vinante in Closing the Gap – Episode 2: Perimenopause and Menopause Are Not Diseases 👉 https://lnkd.in/gQP8-ccq #WomensBrainFoundation #ClosingTheGap #BrainHealth #PrecisionMedicine #WomenInScience #Menopause #Prevention #WomensHealth #FromResearchToCare

⚕️ Unopposed Estrogen: A Preventable Pathway to Malignancy In clinical medicine, some errors are not merely oversights—they are systemic breaches of standard care. One of the most concerning examples continues to appear in women’s health: prescribing steroidal or estrogenic therapy without concurrent progesterone in women who retain their uterus. This isn’t a theoretical debate. It is a well-established oncogenic risk. Decades of endocrinologic and gynecologic evidence confirm that unopposed estrogen exposure leads to endometrial hyperplasia, atypia, and progression to carcinoma. The mechanism is predictable—prolonged endometrial stimulation without counter-regulation—and the outcome is entirely preventable. When such errors occur, they trigger a cascade of medical and ethical consequences. Patients must undergo hysteroscopy, endometrial biopsy, transvaginal imaging, and histopathologic evaluation to rule out malignancy. These interventions, while necessary, are direct sequelae of a prescribing violation, not elective follow-up. Each copay, deductible, and non-covered expense represents a cost of negligence, not care. In pharmacovigilance terms, this constitutes a classifiable adverse event—a foreseeable, preventable medication error with potential for neoplastic outcome. In risk-management terms, it is a breach of clinical protocol and informed-consent integrity. Similar cases continue to surface across ambulatory practices, suggesting gaps in prescribing oversight, EMR alerts, and provider education. The corrective path is clear: • Reinforce dual-hormone safety checks for all systemic estrogen or steroidal prescriptions. • Flag unopposed estrogen orders electronically before release. • Ensure clinician re-training on endometrial malignancy risk and FDA labeling standards. • Mandate reimbursement for diagnostic workups arising from preventable hormonal exposure. Clinical accountability demands that such scenarios never recur. The prevention of iatrogenic malignancy begins not in oncology, but at the point of prescription. #WomensHealth #ClinicalGovernance #Pharmacovigilance #PatientSafety #Endocrinology #MedicalEthics #StandardOfCare #HormoneTherapy #Oncology #HealthcareAccountability

⚖️ When Hormone Therapy Crosses the Legal Line: Duty, Negligence, and Patient Rights in Women’s Health When a woman with an intact uterus is prescribed steroidal or estrogenic therapy without progesterone, the danger isn’t theoretical — it’s measurable, foreseeable, and preventable. This clinical misstep, which exposes patients to unopposed estrogen, isn’t just a medical error. It’s a legal breach of duty under well-established federal and state frameworks. Federal law recognizes that medication errors causing foreseeable harm or risk of harm fall within the domain of medical negligence under the Federal Tort Claims Act (28 U.S.C. § 1346) and the Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.), when labeling and prescribing contradict approved usage. The FDA’s labeling for systemic estrogen explicitly warns that estrogen without a progestogen increases the risk of endometrial carcinoma—making such prescribing practices indefensible when the uterus is intact. Across jurisdictions, the legal principles align: • California: Civil Code § 1714 imposes liability for acts or omissions that foreseeably cause harm; courts have applied this to medication and treatment errors. • New York: Public Health Law § 2805-d defines medical malpractice to include any deviation from accepted medical practice resulting in injury or necessary medical intervention. • Texas: The Texas Civil Practice & Remedies Code § 74.001–74.503 codifies the standard of care and damages for health-care liability claims, encompassing negligent prescribing and failure to warn. Nationwide, courts have also adopted the Medical-Monitoring Doctrine, recognizing compensation for diagnostic evaluations required to rule out serious disease following negligent exposure. Notably, Petito v. A.H. Robins Co. (Fla. 3d DCA 1999) and Ayers v. Jackson Township (New Jersey 1987) affirm that patients can recover the costs of medical surveillance even before disease manifests. For clinicians, strict adherence to evidence-based hormone protocols is both a clinical and legal imperative. For patients, diagnostic costs incurred to rule out malignancy following unopposed hormone exposure are recoverable damages, not incidental expenses. For legal practitioners, these cases highlight a clear intersection of pharmacologic negligence, failure of informed consent, and compensable medical monitoring under federal and state tort law. Errors in hormone therapy don’t merely violate guidelines—they breach the legal duty to protect patients from foreseeable malignancy. Prevention begins where the prescription is written. #WomensHealth #MedicalLaw #PatientRights #ClinicalAccountability #StandardOfCare #HormoneTherapy #Pharmacovigilance #HealthcareCompliance #MedicalEthics #OncologyRisk

“A future goal is for women to have the option to control their menopausal timing, promoting reproductive longevity and reducing symptomatic transitions.” – Magnolia Pretell-Woodhouse This is the HyperHumanHealth era. In 2035, women will have greater control over when they enter menopause and how they experience the transition. From ovarian rejuvenation therapies and cognitive health tracking to 'menopause mode' smart homes, the next decade will be defined by hyper-personalised, predictive, and ethical health ecosystems. Read what other transformations the HyperHumanHealth era will bring in The Future of Menopause 2035: https://lnkd.in/dKfHEEg9

New research presented at #TMS2025, annual meeting of The Menopause Society, links menopause to a higher prevalence of dry eye disease, suggesting hormonal changes may contribute to ocular discomfort in midlife women. #Menopause #EyeHealth Read more: https://lnkd.in/dx-WFBWa

Shelly Brown and Oscar Health are dedicated to addressing the challenges of #chronicillness, aiming to lower out-of-pocket costs for members, ensuring that financial barriers to care are minimized. #WorksiteMarketing #HealthManagement

How to Identify Women at High Risk in Menopause As a woman going through this stage myself, I know how important it is to understand the risks that come with menopause. In this story, I’ll share how to identify women who may be at higher risk—whether it’s for osteoporosis, heart disease, or severe menopausal symptoms. Awareness and early action can make a big difference in protecting our health and well-being. October is a month of awareness, empowerment, and conversation, and I’m grateful to be part of that dialogue. You can also listen to my full story on Under the Hood of Bone Health with Dr. Bernie Russell here: https://lnkd.in/eXzNzuYA #menopause #menopausejourney #menopauseawareness #bonehealth #womenshealth #healthyaging

#menopauseawarenessmonth might be over, but we're not done talking about menopause. Claire Gill, CEO of Bone Health and Osteoporosis Foundation and Founder of National Menopause Foundation, has long been a powerful advocate for women and women's health. In GCOA and WISE Council's "Paving the Path for Women in the Silver Economy: Stories of Leadership, Vision, and Action," Claire asks women to speak up and advocate for themselves—in the workplace, at home, and with healthcare providers—the way they already do for the people they care about. "I kept running into this expectation that we’re supposed to go through menopause quietly. But I’ve never done anything quietly, and I’m not starting now." Read Claire's story here: https://lnkd.in/gtNmwG7r

Despite its broad physical and cognitive impacts, menopause remains under-treated, with low access to care and persistent stigma. But new models are beginning to shift that reality, prioritizing long-term health through proactive screening, cross-specialty care, and evidence-based treatment. BCG’s new publication, written by Sarah Chamberlain, Alexandra Friedman, Trish Stroman, and Beth Viner, makes the case for why improving menopause care is not only urgent, but investable. Learn more: https://lnkd.in/eV-tBCgk